During the past decade, Baylor Endocrine Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 10 clinical trials were completed, i.e. on average, 333.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Baylor Endocrine Center" #1 sponsor was "Mannkind Corporation" with 6 trials, followed by "Orexigen Therapeutics, Inc" with 3 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "InteKrin Therapeutics, Inc." with 2 trials sponsored and "Biodel" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Baylor Endocrine Center" #1 collaborator was "Becton, Dickinson and Company" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Centers for Disease Control and Prevention" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Medpace, Inc." with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Baylor Endocrine Center" are "Diabetes Mellitus, Type 2" (4 trials), "Obesity" (4 trials), "Type 2 Diabetes" (4 trials), "Overweight" (3 trials) and "Comparative Effectiveness of Glycemia-lowering Medications" (1 trials). Many other conditions were trialed in "Baylor Endocrine Center" in a lesser frequency.

Most popular intervention types in "Baylor Endocrine Center" are "Drug" (16 trials), "Behavioral" (3 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Technosphere Insulin" (3 trials), "Ancillary therapy" (2 trials), "Technosphere® Insulin Inhalation Powder" (2 trials) and "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Baylor Endocrine Center" are 19 trials for "All" genders.

Currently, there are NaN active trials in "Baylor Endocrine Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Baylor Endocrine Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Baylor Endocrine Center, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".